Abstract 672P
Background
The functional activation and migration of T cells, which are enhanced by immune checkpoint inhibitors (ICIs), are regulated by the circadian rhythm. Therefore, the administration time of ICIs may affect their therapeutic efficacy. Some retrospective studies involving non-small cell lung cancer (NSCLC) patients reported that those who received nivolumab earlier in the day had significantly longer overall survival (OS) and progression-free survival (PFS) compared to those who received it later in the day. In this study, we investigated the association between the administration time of ICIs and therapeutic efficacy in a larger cohort of NSCLC patients who received nivolumab.
Methods
This retrospective study included patients with NSCLC who started to receive nivolumab between December 2015 and December 2018 at two Japanese institutions. Patients who started nivolumab administration by 12:00 for at least two out of the first three courses were classified as the morning administration group, while those who did not were classified as the afternoon administration group. OS and PFS were compared between the two groups. We also conducted analyses using different cut-off time for “morning” and “afternoon”.
Results
Out of 345 NSCLC patients who received nivolumab, analysis was conducted on 257 patients who completed at least three courses. 107 (41.7%) patients were assigned to the morning administration group, and 150 (58.3%) to the afternoon administration group. There were no significant differences in OS and PFS between the morning and afternoon groups (median OS: 16.9 months vs. 14.2 months; HR, 0.89; 95% CI, 0.85-1.48; p=0.409) (median PFS: 4.2 months vs. 4.7 months; HR, 1.08; 95% CI, 0.71-1.19; p=0.554). Similar analysis with the cut-off times set at 13:00 and 14:00 also showed no significant differences in OS and PFS.
Conclusions
In patients with NSCLC treated with nivolumab, there were no differences in OS or PFS based on the administration time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
A. Tamiya: Financial Interests, Personal, Invited Speaker: AstraZeneca, Ono Pharmaceutical, MSD, Chugai Pharmaceutical, Novartis, Taiho Pharmaceutical, Boehringer Ingelheim, Kyowa Kirin, Eli Lilly, Daiichi Sankyo, Nihon-Kayaku, Pfizer, Amgen, Takeda, Merck Pharma, Thermo Fischer, Bristol Myers Squibb. M. Tamiya: Financial Interests, Personal, Invited Speaker: AstraZeneca, Ono Pharmaceutical, MSD, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Bristol Myers Squibb, Novartis, Kyowa Kirin, Nihon-Kayaku, Takeda, Merck BioPharma. Y. Taniguchi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Ono Pharmaceutical, MSD, Chugai Pharmaceutical, Bristol Myers Squibb. K. Okishio: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Nihon-Kayaku, Takeda, Taiho Pharmaceutical, Sawai Pharmaceutical. All other authors have declared no conflicts of interest.